Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Optiscan Imaging Limited specializes in the development and market introduction of confocal microscopy technology, applied across both clinical and pre-clinical settings in Australia, Germany, and other global regions. A notable offering is the FIVE2 (ViewnVivo) system, a compact confocal endomicroscope utilized for a broad range of research, including clinical, translational, and pre-clinical studies. Additionally, the company is actively developing the InVivage device, which is intended for use in cancer screening and surgical procedures. Established in 1994, Optiscan Imaging Limited maintains its headquarters in Mulgrave, Australia.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.